The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
复制标题

头颈癌中 PD-1/PD-L1 通路的演变

DOI:
10.3389/fimmu.2020.01721
复制
发表时间:
2020
影响因子:
7.3
通讯作者:
Tang YL
Tang YL
中科院分区:
医学2区
文献类型:
--
作者:
Qiao XW;Jiang J;Pang X;Huang MC;Tang YJ;Liang XH;Tang YL

文献摘要

参考文献

被引文献

相似文献

在过去的10年里,癌症免疫治疗在多种癌症类型中取得了重大进展,并逐步应用于临床癌症治疗,其中程序性细胞死亡蛋白-1(PD-1)/程序性细胞死亡配体1(PD-L1)通路是最受关注的靶点之一。与传统疗法相比,PD-1/PD-L1阻断免疫疗法对晚期头颈部鳞状细胞癌(HNSCC)患者具有更满意的疗效和更低的毒性。本文分析了PD-1/PD-L1在HNSCC中的表达特点和临床意义,以及表达PD-1/PD-L1的肿瘤细胞和基质细胞在HNSCC中的免疫抑制作用,并介绍了PD-1/PD-L1抑制剂的发展前景,以期为复发或转移性HNSCC的治疗提供新的选择。
Over the past 10 years, cancer immunotherapy has made significant progress in multiple cancer types and has been gradually been applied to clinical cancer care, in which the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is one of the most attractive targets. Compared with traditional therapies, the emerging PD-1/PD-L1 blockade immunotherapy exhibited more satisfactory curative effects and lower toxicity for patients with advanced head and neck squamous cell carcinoma (HNSCC). This review analyzes the expression characteristics and clinical significance of PD-1/PD-L1 in HNSCC, the immunosuppressive roles of tumor cell and stromal cell expressing PD-1/PD-L1 in this disease, and presents the development landscape of PD-1/PD-L1 inhibitors, which may provide new curative alternatives for recurrent or metastatic HNSCC.
DOI: 10.1183/13993003.01298-2018
发表时间: 2019-02-01
影响因子: 24.3
作者:
Cubillos-Zapata, Carolina;Angel Martinez-Garcia, Miguel;Garcia-Rio, Francisco
通讯作者: Garcia-Rio, Francisco
DOI: 10.1007/s40265-013-0025-3
发表时间: 2013-01-01
期刊: DRUGS
影响因子: 11.5
作者:
Dorsey, Kelly;Agulnik, Mark
通讯作者: Agulnik, Mark
DOI: 10.1038/ni.1679
发表时间: 2009-01
期刊: NATURE IMMUNOLOGY
影响因子: 30.5
作者:
Blackburn, Shawn D.;Shin, Haina;Haining, W. Nicholas;Zou, Tao;Workman, Creg J.;Polley, Antonio;Betts, Michael R.;Freeman, Gordon J.;Vignali, Dario A. A.;Wherry, E. John
通讯作者: Wherry, E. John
DOI: 10.1016/j.oraloncology.2019.104460
发表时间: 2019-12
期刊: Oral oncology
影响因子: 4.8
作者:
Cramer JD;Burtness B;Ferris RL
通讯作者: Ferris RL
DOI: 10.1038/nature23643
发表时间: 2017-09-07
期刊: Nature
影响因子: 64.8
作者:
Burr ML;Sparbier CE;Chan YC;Williamson JC;Woods K;Beavis PA;Lam EYN;Henderson MA;Bell CC;Stolzenburg S;Gilan O;Bloor S;Noori T;Morgens DW;Bassik MC;Neeson PJ;Behren A;Darcy PK;Dawson SJ;Voskoboinik I;Trapani JA;Cebon J;Lehner PJ;Dawson MA
通讯作者: Dawson MA